HRP20100301T1 - Ciklopeptidni derivati sa anti-integrinskom aktivnošću - Google Patents
Ciklopeptidni derivati sa anti-integrinskom aktivnošću Download PDFInfo
- Publication number
- HRP20100301T1 HRP20100301T1 HR20100301T HRP20100301T HRP20100301T1 HR P20100301 T1 HRP20100301 T1 HR P20100301T1 HR 20100301 T HR20100301 T HR 20100301T HR P20100301 T HRP20100301 T HR P20100301T HR P20100301 T1 HRP20100301 T1 HR P20100301T1
- Authority
- HR
- Croatia
- Prior art keywords
- phe
- group
- gly
- asp
- arg
- Prior art date
Links
- 102000001189 Cyclic Peptides Human genes 0.000 title claims abstract 3
- 108010069514 Cyclic Peptides Proteins 0.000 title claims abstract 3
- 239000000203 mixture Substances 0.000 claims abstract 5
- CSJZKSXYLTYFPU-LLVKDONJSA-N (2r)-2-azaniumyl-3-(4-tert-butylphenyl)propanoate Chemical compound CC(C)(C)C1=CC=C(C[C@@H]([NH3+])C([O-])=O)C=C1 CSJZKSXYLTYFPU-LLVKDONJSA-N 0.000 claims abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims abstract 2
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract 2
- 125000004122 cyclic group Chemical group 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 102000006495 integrins Human genes 0.000 claims 3
- 108010044426 integrins Proteins 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000002141 anti-parasite Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003096 antiparasitic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 208000021328 arterial occlusion Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000003683 cardiac damage Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 238000010647 peptide synthesis reaction Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
- 239000007790 solid phase Substances 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Ciklični peptidi koji imaju slijedeću Formulu I: c(R1-Arg-Gly-Asp-R2) (Formula I), naznačeni time, što: c znači ciklični; R1 je amino-kiselina opće formule: -NX-CY(Z)-CO-; gdjeX je odabrano iz grupe koja sadrži: H, linearni ili razgranati C1-C6 alkil, C6-C10 aril, benzil, (CH2)n-COR, (CH2)n-NHR', 4-COR-benzil, 4-(CH2-NHR')-benzil; gdje je n cijeli broj od 1 do 5; Y je odabrano iz grupe koja sadrži: H, CHmFm', gdje je m + m' = 3, gdje su m i m' cijeli brojevi od 0 do 3; Z je odabrano iz grupe koja sadrži: H, (CH2)n1-NHR', 4-NHR'-(CH2)n1-benzil, 4-COR-benzil, gdje je n1 cijeli broj od 0 do 5; R je odabrano iz grupe koja sadrži W, OW, N[CH2-CO-NH-CH2-O-(CH2CH2O)n2-CH2-COOW]2, NH-CH2-O-(CH2CH2O)n2-CH2-COOW, NW-(CH2-CH2NH)n2-CH2CH2NHW; gdje je n2 cijeli broj od 1 do 22; iW je odabrano iz grupe koja sadrži : H, C1-C3 alkil; R' je odabrano iz grupe koja sadrži H, CO-(CH2)n2-COOW, CO-CH2-O-(CH2CH2O)n2-CH2-NHW, CO-CH2-O-(CH2CH2O)n2-CH2-COOW; gdje n2 ima značenje navedeno gore; iR2 je odabrano iz grupe koja sadrži: D-Phe, D-4-tert-butil-Phe, D-4-CF3-Phe, D-4- acetilamin-Phe; njihove racemske smjese, njihove pojedinačne enantiomere, njihove pojedinačne dijastereoizomere i njihove farmaceutski prihvatljive soli. Patent sadrži još 14 patentnih zahtjeva.
Claims (15)
1. Ciklični peptidi koji imaju slijedeću Formulu I:
c(R1-Arg-Gly-Asp-R2) (Formula I),
naznačeni time, što:
c znači ciklični;
R1 je amino-kiselina opće formule: -NX-CY(Z)-CO-; gdje
X je odabrano iz grupe koja sadrži: H, linearni ili razgranati C1-C6 alkil, C6-C10 aril, benzil, (CH2)n-COR, (CH2)n-NHR', 4-COR-benzil, 4-(CH2-NHR')-benzil; gdje je n cijeli broj od 1 do 5;
Y je odabrano iz grupe koja sadrži: H, CHmFm', gdje je m + m' = 3, gdje su m i m' cijeli brojevi od 0 do 3;
Z je odabrano iz grupe koja sadrži: H, (CH2)n1-NHR', 4-NHR'-(CH2)n1-benzil, 4-COR-benzil, gdje je n1 cijeli broj od 0 do 5;
R je odabrano iz grupe koja sadrži W, OW, N[CH2-CO-NH-CH2-O-(CH2CH2O)n2-CH2-COOW]2, NH-CH2-O-(CH2CH2O)n2-CH2-COOW, NW-(CH2-CH2NH)n2-CH2CH2NHW; gdje je n2 cijeli broj od 1 do 22; i
W je odabrano iz grupe koja sadrži : H, C1-C3 alkil;
R' je odabrano iz grupe koja sadrži H, CO-(CH2)n2-COOW, CO-CH2-O-(CH2CH2O)n2-CH2-NHW, CO-CH2-O-(CH2CH2O)n2-CH2-COOW; gdje n2 ima značenje navedeno gore; i
R2 je odabrano iz grupe koja sadrži: D-Phe, D-4-tert-butil-Phe, D-4-CF3-Phe, D-4- acetilamin-Phe;
njihove racemske smjese, njihove pojedinačne enantiomere, njihove pojedinačne dijastereoizomere i njihove farmaceutski prihvatljive soli.
2. Spoj prema zahtjevu 1, naznačen time, što je odabran iz grupe koja se sastoji od:
c(Arg-Gly-Asp-D-Phe-Amp);
c(Arg-Gly-Asp-D-Phe-N-Me-Amp);
c[Arg-Gly-Asp-D-Phe-Amp-CO(CH2)2COOH];
c(Arg-Gly-Asp-D-Phe-N-Amb-Gly);
c[Arg-Gly-Asp-D-Phe-Amp-(CO-CH2-(O-CH2-CH2)2-O-CH2-COOH];
c[Arg-Gly-Asp-D-Phe-Amp-(CO-CH2-(OCH2CH2)8-OCH2-COOH]; i
3. Spojevi, naznačeni time, što imaju formulu:
c[Arg-Gly-Asp-D-Phe-Amp(CO-CH2-(OCH2-CH2)3-OCH3)];
c(Arg-Gly-Asp-D-Phe-Aad);
4. Postupak za pripremanje peptida prema zahtjevima 1-3, naznačen time, što obuhvaća sintezu linearnog peptida i njegovu ciklizaciju poslije toga.
5. Postupak prema zahtjevu 4, naznačen time, što se sinteza peptida obavlja u čvrstoj fazi ili u otopini.
6. Upotreba spojeva prema zahtjevima 1-3, naznačena time, što se upotrebljavaju kao lijekovi.
7. Farmaceutske kompozicije, naznačene time, što sadrže bar jedan spoj prema zahtjevu 1 ili 2 ili 3 u smjesi sa farmaceutski prihvatljivim ekscipijentom ili nosačem
8. Kompozicije prema zahtjevu 7, naznačene time, što dodatno sadrže lijek odabran iz grupe koja se sastoji od antikancerskih, antiparazitskih ili antivirusnih sredstava, u odvojenim formama ili u jednoj doznoj formi.
9. Upotreba spojeva prema zahtjevima 1-3, nazančena time, što se koriste za pripremanje lijekova koji pokazuju inhibitornu akivnost prema integrinskim receptorima.
10. Upotreba spojeva prema zahtjevu 9, naznačena time, što se spomenuti lijek koristi za liječenje bolesti nastalih zbog abnormalne angiogeneze.
11. Upotreba prema zahtjevu 10, naznačena time, što je spomenuta bolest odabrana iz grupe koja se sastoji od tumora koji u višku eksprimiraju integrine, prirodno i na inducirani način, upalnih oblika (npr. reumatski artritis), bolesti oka, retinopatije, akutne bubrežne insuficijencije, osteoporoze i matastaze, kardiovaskularne bolesti (moždani udar i oštećenje srca).
12. Upotreba spojeva prema zahtjevima 1-3, naznačena time, što se koriste za pripremu lijeka sa antiparazitskom aktivnošću preko inhibicije integrina.
13. Kompozicija, naznačena time, što sadrži radioaktivno obilježene derivate spojeva prema zahtjevima 1 ili 2 ili 3.
14. Upotreba radioaktivno obilježenih derivata spojeva prema zahtjevima 1 ili 2 ili 3, naznačena time, što se koriste za pripremanje dijagnostičkih sredstava.
15. Upotreba prema zahtjevu 14, naznačena time, što se spomenuto dijagnostičko sredstvo koristi za detekciju malih tumornih masa ili slučajeva okluzija arterija.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000239A ITRM20040239A1 (it) | 2004-05-13 | 2004-05-13 | Derivati ciclopeptidici ad attivita' antintegrine. |
| PCT/IT2005/000262 WO2005111064A1 (en) | 2004-05-13 | 2005-05-04 | Cyclopeptide derivatives with anti-integrin activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100301T1 true HRP20100301T1 (hr) | 2010-06-30 |
Family
ID=34968013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100301T HRP20100301T1 (hr) | 2004-05-13 | 2010-05-27 | Ciklopeptidni derivati sa anti-integrinskom aktivnošću |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20070178045A1 (hr) |
| EP (1) | EP1751176B1 (hr) |
| JP (1) | JP2008500971A (hr) |
| KR (1) | KR20070012524A (hr) |
| CN (1) | CN1953990A (hr) |
| AR (1) | AR048957A1 (hr) |
| AT (1) | ATE460426T1 (hr) |
| AU (1) | AU2005243418A1 (hr) |
| BR (1) | BRPI0510985A (hr) |
| CA (1) | CA2562576A1 (hr) |
| CY (1) | CY1110039T1 (hr) |
| DE (1) | DE602005019876D1 (hr) |
| DK (1) | DK1751176T3 (hr) |
| ES (1) | ES2340862T3 (hr) |
| HR (1) | HRP20100301T1 (hr) |
| IT (1) | ITRM20040239A1 (hr) |
| MX (1) | MXPA06012887A (hr) |
| PL (1) | PL1751176T3 (hr) |
| PT (1) | PT1751176E (hr) |
| RS (1) | RS51300B (hr) |
| SI (1) | SI1751176T1 (hr) |
| TW (1) | TW200606178A (hr) |
| WO (1) | WO2005111064A1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2008010303A (es) * | 2006-02-09 | 2009-03-05 | Enzon Pharmaceuticals Inc | Conjugados polimericos multi brazos de 7-etil-10-hidroxicamptoteci na para el tratamiento de canceres de mama, colorrectal, pancreatico, ovarico y de pulmon. |
| EP1961759A1 (en) * | 2007-02-21 | 2008-08-27 | Universita'degli Studi Di Milano | Integrin targeted cyclopeptide ligands, their preparation and use |
| TWI474819B (zh) * | 2012-05-15 | 2015-03-01 | Univ Nat Cheng Kung | 調控物及含有該調控物之醫藥組合物 |
| JP2016515120A (ja) * | 2013-03-15 | 2016-05-26 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | 抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防 |
| CN103588863B (zh) * | 2013-11-15 | 2016-08-17 | 苏州强耀生物科技有限公司 | Rgd环肽合成制备工艺 |
| WO2022183360A1 (en) * | 2021-03-02 | 2022-09-09 | Tsao Yeou Ping | Short synthetic peptide and their uses for treating dry eye disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4310643A1 (de) * | 1993-04-01 | 1994-10-06 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
| US5449761A (en) * | 1993-09-28 | 1995-09-12 | Cytogen Corporation | Metal-binding targeted polypeptide constructs |
| US6027711A (en) * | 1995-06-07 | 2000-02-22 | Rhomed Incorporated | Structurally determined metallo-constructs and applications |
| DE19725368A1 (de) * | 1997-06-16 | 1998-12-17 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren und deren Verwendung für bildgebende Verfahren |
| ITRM20040242A1 (it) * | 2004-05-13 | 2004-08-13 | Ist Naz Stud Cura Dei Tumori | "7-t-butossiimminometilcamptotecina coniugata in posizione 20 con antagonisti delle integrine. |
| ITRM20040240A1 (it) * | 2004-05-13 | 2004-08-13 | Ist Naz Stud Cura Dei Tumori | Camptotecine coniugate in posizione 7 con antagonisti delle integrine. |
-
2004
- 2004-05-13 IT IT000239A patent/ITRM20040239A1/it unknown
-
2005
- 2005-05-04 MX MXPA06012887A patent/MXPA06012887A/es active IP Right Grant
- 2005-05-04 KR KR1020067025228A patent/KR20070012524A/ko not_active Application Discontinuation
- 2005-05-04 US US11/596,190 patent/US20070178045A1/en not_active Abandoned
- 2005-05-04 EP EP05742999A patent/EP1751176B1/en active Active
- 2005-05-04 AU AU2005243418A patent/AU2005243418A1/en not_active Abandoned
- 2005-05-04 DK DK05742999.5T patent/DK1751176T3/da active
- 2005-05-04 BR BRPI0510985-0A patent/BRPI0510985A/pt not_active IP Right Cessation
- 2005-05-04 ES ES05742999T patent/ES2340862T3/es active Active
- 2005-05-04 TW TW094114404A patent/TW200606178A/zh unknown
- 2005-05-04 JP JP2007512736A patent/JP2008500971A/ja not_active Withdrawn
- 2005-05-04 PT PT05742999T patent/PT1751176E/pt unknown
- 2005-05-04 SI SI200530986T patent/SI1751176T1/sl unknown
- 2005-05-04 WO PCT/IT2005/000262 patent/WO2005111064A1/en active Application Filing
- 2005-05-04 DE DE602005019876T patent/DE602005019876D1/de active Active
- 2005-05-04 CA CA002562576A patent/CA2562576A1/en not_active Abandoned
- 2005-05-04 RS RSP-2010/0231A patent/RS51300B/sr unknown
- 2005-05-04 CN CNA2005800152380A patent/CN1953990A/zh active Pending
- 2005-05-04 AT AT05742999T patent/ATE460426T1/de not_active IP Right Cessation
- 2005-05-04 PL PL05742999T patent/PL1751176T3/pl unknown
- 2005-05-13 AR ARP050101955A patent/AR048957A1/es unknown
-
2010
- 2010-05-19 CY CY20101100440T patent/CY1110039T1/el unknown
- 2010-05-27 HR HR20100301T patent/HRP20100301T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2562576A1 (en) | 2005-11-24 |
| KR20070012524A (ko) | 2007-01-25 |
| BRPI0510985A (pt) | 2007-12-04 |
| CN1953990A (zh) | 2007-04-25 |
| RS51300B (sr) | 2010-12-31 |
| MXPA06012887A (es) | 2007-02-15 |
| US20070178045A1 (en) | 2007-08-02 |
| ATE460426T1 (de) | 2010-03-15 |
| DK1751176T3 (da) | 2010-06-14 |
| AR048957A1 (es) | 2006-06-14 |
| AU2005243418A1 (en) | 2005-11-24 |
| WO2005111064A1 (en) | 2005-11-24 |
| DE602005019876D1 (de) | 2010-04-22 |
| WO2005111064A8 (en) | 2006-02-09 |
| PL1751176T3 (pl) | 2010-08-31 |
| TW200606178A (en) | 2006-02-16 |
| CY1110039T1 (el) | 2012-05-23 |
| ITRM20040239A1 (it) | 2004-08-13 |
| JP2008500971A (ja) | 2008-01-17 |
| EP1751176A1 (en) | 2007-02-14 |
| ES2340862T3 (es) | 2010-06-10 |
| EP1751176B1 (en) | 2010-03-10 |
| SI1751176T1 (sl) | 2010-06-30 |
| PT1751176E (pt) | 2010-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100301T1 (hr) | Ciklopeptidni derivati sa anti-integrinskom aktivnošću | |
| RU2403258C2 (ru) | Тиазолилдигидроиндазолы | |
| JP6754071B2 (ja) | メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用 | |
| DE69912313T2 (de) | Colchinolderivate als gefässschädigende mittel | |
| DE60214718T2 (de) | Verbindungen mit taxol-verstärkender wirkung | |
| RU2201224C2 (ru) | Соединения, активные в новом сайте на рецептор-регулируемых кальциевых каналах и используемые для лечения неврологических расстройств и заболеваний | |
| ES2408597T3 (es) | 1,2,3-triazoles inhibidores de la polimerización de la tubulina para el tratamiento de trastornos proliferativos | |
| RU2003137593A (ru) | Соединения на основе пептидов для направленной доставки к рецепторам интегринов | |
| JPS6339855A (ja) | Ａｃｅ阻害剤の抗高血圧活性を高める医薬組成物 | |
| CN101365461B (zh) | 舒林酸衍生物、其用途和其制备 | |
| RU2002101723A (ru) | Инданилзамещенные бензолкарбонамиды, способ их получения, их применение в качестве лекарственного средства, а также содержащие их фармацевтические композиции | |
| EA200500088A1 (ru) | Трициклические модуляторы ядерного рецептора стероидного гормона | |
| JP2016516772A (ja) | オキサシクロヘプタン及びオキサビシクロヘプテンの配合物 | |
| CN102498094A (zh) | 胍法辛的前药 | |
| HRP20050544A2 (en) | Solid drug for oral use | |
| JP2020508985A5 (hr) | ||
| EA201201414A1 (ru) | КОМБИНАЦИИ, СОДЕРЖАЩИЕ ЗАМЕЩЕННЫЕ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНЫ | |
| CN109415353A (zh) | 聚乙二醇化卡非佐米化合物 | |
| RU2011105810A (ru) | Азотсодержащие бициклические гетероциклические соединения | |
| CA2836915A1 (en) | Emetine derivatives, prodrugs containing same, and methods of treating conditions using same | |
| JP2008500971A5 (hr) | ||
| JP2008501023A (ja) | 小児患者での癌の治療 | |
| TW475897B (en) | A composition for inducing cell of neoplastic cells | |
| JP2009534449A (ja) | １，４−ナフトキノン系化合物、該化合物を含んでなる組成物、およびこれらの化合物の抗がん剤としての使用 | |
| CN109952287A (zh) | Mtor-deptor相互作用的抑制剂及其使用方法 |